GANX Stock Risk & Deep Value Analysis
Gain Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About GANX Stock
We analyzed Gain Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran GANX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
GANX Risk Analysis & Red Flags
What Could Go Wrong
Despite positive Phase 1b data, the company is burning approximately $20 million annually with $20.8 million cash on hand (as of Dec 31, 2025). Without a substantial capital raise or a significant non-dilutive partnership within the next 12-18 months, the company will face severe liquidity issues, leading to significant shareholder dilution or potential cessation of operations.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
High
Red Flags
- ⚠
Persistent net losses and high cash burn without clear path to profitability
- ⚠
Reliance on future equity raises for continued operations
- ⚠
Lead candidate (GT-02287) is still in early clinical stages (moving to Phase 2)
- ⚠
No major strategic partnerships announced despite platform potential
Upcoming Risk Events
- 📅
Delays in FDA IND clearance or Phase 2 initiation
- 📅
Negative or inconclusive Phase 2 clinical data
- 📅
Failure to secure sufficient additional financing to fund operations past 2027
When to Reconsider
- 🚪
Exit if GT-02287 clinical trials face significant delays or negative data readouts
- 🚪
Sell if cash balance drops below $10 million without a new funding announcement by mid-2027
- 🚪
Exit if the company fails to initiate Phase 2 for GT-02287 by Q1 2027
Unlock GANX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Gain Therapeutics Inc (GANX) Do?
Market Cap
$90.40M
Sector
Healthcare
Industry
Biotechnology
Employees
23
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Visit Gain Therapeutics Inc WebsiteInvestment Thesis
Gain Therapeutics represents a compelling, albeit speculative, investment in a platform biotechnology company addressing critical unmet needs in CNS and rare diseases. The positive Phase 1b data for GT-02287, coupled with a solid cash runway (relative to prior perception) and clear clinical milestones ahead, positions the company for significant re-rating potential. Success in Phase 2 and beyond, or a strategic partnership, could unlock substantial value from its current low market capitalization.
Is GANX Stock Undervalued?
Unlock the full AI analysis for GANX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
GANX Price Targets & Strategy
12-Month Target
$5.50
Bull Case
$10.00
Bear Case
$1.00
Valuation Basis
Implied market cap of $242M, reflecting successful transition to Phase 2 for GT-02287 and continued platform validation.
Entry Strategy
Dollar-cost average between $1.80-$2.20, leveraging any dips post Q1 earnings or during broader market volatility.
Exit Strategy
Consider taking initial profits at $5.00-$6.00; reassess upon Phase 2 initiation. Stop-loss at $1.50 if clinical or financial news turns negative.
Portfolio Allocation
2% for aggressive risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is GANX Financially Healthy?
Valuation
P/E Ratio
-3.20
PEG Ratio
-0.06
Price/Book
4.30
Profitability
Operating Margin
-6506.25%
Net Margin
-6393.75%
Return on Equity
-289.11%
EPS
$-0.65
Balance Sheet
Current Ratio
6.63
Quick Ratio
6.46
Debt/Equity
0.02
Cash & Equivalents
$20.80M
Cash Flow
EBITDA
-$18.62M
Other
Beta (Volatility)
0.20
Does GANX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The proprietary SEE-Tx® platform provides a unique approach to identifying and developing small molecule therapies for challenging targets. Successful clinical translation, particularly for GT-02287, will validate the platform and strengthen its IP-derived moat, making it harder for competitors to replicate.
Moat Erosion Risks
- •Failure of the SEE-Tx® platform to yield further viable drug candidates or clinical success
- •Competitors developing similar allosteric modulation technologies or alternative therapeutic approaches
- •Challenges in patent protection or intellectual property disputes
GANX Competitive Moat Analysis
Sign up to see competitive advantages
GANX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - The positive clinical data is likely generating some positive buzz, but without widespread analyst coverage, retail sentiment is likely mixed and speculative.
Institutional Sentiment
Neutral - No analyst consensus or institutional buying data provided, but officer option grants suggest internal confidence in future value.
Insider Activity (Form 4)
CEO Gene Mack granted 200,000 employee stock options on 2026-03-26 (exercise price $1.86/share). Officer Gianluca Fuggetta granted 50,000 employee stock options on 2026-03-26 (exercise price $1.86/share). No open market buys or sells reported in the last 90 days.
Options Flow
Normal options activity - No specific unusual options activity reported in the provided research.
Earnings Intelligence
Next Earnings
2026-05-13
Surprise Probability
Medium
Historical Earnings Pattern
Specific historical patterns are unavailable. However, for early-stage biotechs, clinical updates and pipeline progress often exert a greater influence on stock price than financial results.
Key Metrics to Watch
Competitive Position
Top Competitor
DNLI
Market Share Trend
N/A - Company is pre-commercial.
Valuation vs Peers
Trading at a significant discount to more advanced biotech peers due to early-stage pipeline and lack of revenue, but with higher potential upside if clinical catalysts are met.
Competitive Advantages
- •Proprietary SEE-Tx® drug discovery platform
- •Unique allosteric modulation approach for misfolded proteins
- •Positive early clinical data for lead Parkinson's candidate
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive GANX Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings on 2026-05-13
- •FDA IND Clearance for GT-02287 (expected 2Q26)
- •Phase 2 Initiation for GT-02287 (expected 3Q26)
Medium-Term (6-18 months)
- •Interim Phase 2 data readouts for GT-02287 (late 2027/early 2028)
- •Potential strategic partnership for GT-02287
- •Pipeline expansion with additional candidates from SEE-Tx® platform
Long-Term (18+ months)
- •Phase 3 initiation for GT-02287
- •Regulatory approval and commercialization for GT-02287
- •Disease-modifying impact in Parkinson's validating SEE-Tx® platform
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for GANX?
- ✓
Continued positive clinical progress and data readouts for GT-02287
- ✓
Announcement of a strategic partnership or non-dilutive financing
- ✓
Expansion of the drug pipeline leveraging the SEE-Tx® platform
Bull Case Analysis
See what could go right with Premium
Competing with GANX
See how Gain Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Gain Therapeutics Inc GANX | $90.4M | 5.7 | -3.2 | $50,000 | -6393.8% | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Denali Therapeutics Inc DNLI | $2.8B | 5.4 | -12.3 | $24.7M | -241.0% | -12.0% | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Gain Therapeutics Inc Makes Money
Gain Therapeutics is a clinical-stage biotechnology company focused on developing novel small molecule drugs to treat diseases caused by protein misfolding, such as Parkinson's and various rare genetic disorders. They leverage their proprietary drug discovery platform, SEE-Tx®, to identify unique 'allosteric' sites on disease-causing proteins, allowing them to design drugs that can restore the proteins' proper function. The company currently generates minimal revenue and is in the research and development phase. Its business model relies on the successful progression of its drug candidates through clinical trials, regulatory approval, and eventual commercialization, potentially through licensing deals with larger pharmaceutical companies or by independently bringing therapies to market.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Gain Therapeutics Inc (GANX)?
As of April 17, 2026, Gain Therapeutics Inc has a DVR Score of 5.7 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Gain Therapeutics Inc?
Gain Therapeutics Inc's market capitalization is approximately $90.4M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Gain Therapeutics Inc use?
GANX is the ticker symbol for Gain Therapeutics Inc. The company trades on the NGM.
What is the risk level for GANX stock?
Our analysis rates Gain Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of GANX?
Gain Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -3.2. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is GANX stock profitable?
Gain Therapeutics Inc has a profit margin of -6393.8%. The company is currently unprofitable.
How often is the GANX DVR analysis updated?
Our AI-powered analysis of Gain Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 17, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for GANX (Gain Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.